Compare HTGC & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTGC | QURE |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.1B |
| IPO Year | 2004 | 2013 |
| Metric | HTGC | QURE |
|---|---|---|
| Price | $16.41 | $21.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $19.50 | ★ $60.37 |
| AVG Volume (30 Days) | 1.0M | ★ 2.4M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | ★ 11.46% | N/A |
| EPS Growth | 14.91 | ★ 29.67 |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $9.32 | $54.78 |
| Revenue Next Year | $7.07 | $356.14 |
| P/E Ratio | $18.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.70 | $8.73 |
| 52 Week High | $19.13 | $71.50 |
| Indicator | HTGC | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 44.57 | 26.55 |
| Support Level | $16.09 | $20.25 |
| Resistance Level | $17.05 | $25.61 |
| Average True Range (ATR) | 0.27 | 1.07 |
| MACD | 0.01 | 0.75 |
| Stochastic Oscillator | 58.61 | 37.92 |
Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.